Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Valneva ( (VALN) ).
On September 30, 2025, Valneva SE announced positive four-year antibody persistence data for its chikungunya vaccine, IXCHIQ®. The data showed that 95% of participants maintained neutralizing antibody titers above the seroresponse threshold, with similar results across different age groups. This long-lasting antibody persistence is a significant advantage for the vaccine, especially in areas prone to chikungunya outbreaks. The trial, supported by CEPI and the EU’s Horizon Europe program, also reported no safety concerns. Valneva aims to expand vaccine access, particularly in low- and middle-income countries, through partnerships such as the one with the Serum Institute of India.
The most recent analyst rating on (VALN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects a mix of positive technical momentum and strategic progress in vaccine development, offset by financial challenges. The company’s strong cash position and revenue growth are promising, but negative profitability and valuation metrics weigh on the score.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is involved in the development of vaccine candidates against diseases such as Lyme disease, Shigella, and Zika virus.
Average Trading Volume: 91,841
Technical Sentiment Signal: Buy
Current Market Cap: $1B
For detailed information about VALN stock, go to TipRanks’ Stock Analysis page.